State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Department of Immunology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Clin Exp Med. 2023 Oct;23(6):1933-1944. doi: 10.1007/s10238-023-01009-0. Epub 2023 Feb 3.
Despite increasing interest in the study of circulating tumor cells (CTC) subsets, especially epithelial-mesenchymal transition (EMT) and stem cells subsets of CTC that play a key role in tumor recurrence and metastasis, there is no evidence from meta-analyses that shows the correlation between stem-like CTCs and prognosis in cancer patients. Thus, we performed a meta-analysis to assess its prognostic value. Sixteen articles were screened by searching the PubMed, Embase, Cochrane, China National Knowledge Internet (CNKI) and Wanfang databases. The hazard ratio (HR) and 95% confidence interval (95% CI) extracted from each article were summarized. Patients with positive stem-like CTCs in peripheral blood had significantly shorter overall survival (OS, HR: 2.58, 95% CI 1.76-3.79, P < 0.00001), progression-free survival (PFS, HR: 2.21, 95% CI 1.26-3.89, P = 0.006) and disease-free survival (DFS, HR: 2.53, 95% CI: 1.12-5.70, P = 0.03). This study provides the first meta-analysis evidence for the prognostic value of stem-like CTCs, demonstrating that these cells are associated with poor prognosis in cancer patients.Systematic review registrationCRD42022322062.
尽管人们对循环肿瘤细胞 (CTC) 亚群的研究越来越感兴趣，特别是在肿瘤复发和转移中起关键作用的上皮-间充质转化 (EMT) 和 CTC 干细胞亚群，但荟萃分析没有证据表明干细胞样 CTCs 与癌症患者的预后相关。因此，我们进行了一项荟萃分析来评估其预后价值。通过搜索 PubMed、Embase、Cochrane、中国国家知识网 (CNKI) 和万方数据库，筛选出 16 篇文章。从每篇文章中提取的风险比 (HR) 和 95%置信区间 (95%CI) 进行了总结。外周血中存在阳性干细胞样 CTC 的患者总生存期 (OS, HR: 2.58, 95% CI 1.76-3.79, P < 0.00001)、无进展生存期 (PFS, HR: 2.21, 95% CI 1.26-3.89, P = 0.006) 和无病生存期 (DFS, HR: 2.53, 95% CI: 1.12-5.70, P = 0.03) 明显缩短。这项研究为干细胞样 CTC 的预后价值提供了首次荟萃分析证据，表明这些细胞与癌症患者的不良预后相关。系统评价注册 CRD42022322062。
